Compare IHS & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IHS | HAE |
|---|---|---|
| Founded | 2001 | 1971 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | 2021 | 1996 |
| Metric | IHS | HAE |
|---|---|---|
| Price | $8.17 | $76.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $8.29 | ★ $84.13 |
| AVG Volume (30 Days) | ★ 1.3M | 750.3K |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.05 |
| Revenue | N/A | ★ $910,373,000.00 |
| Revenue This Year | $17.26 | N/A |
| Revenue Next Year | $7.87 | $5.23 |
| P/E Ratio | ★ $5.85 | $36.26 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.71 | $47.32 |
| 52 Week High | $8.95 | $87.32 |
| Indicator | IHS | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 43.13 | 58.24 |
| Support Level | $8.09 | $72.04 |
| Resistance Level | $8.36 | $80.90 |
| Average True Range (ATR) | 0.08 | 2.87 |
| MACD | -0.00 | -0.39 |
| Stochastic Oscillator | 15.38 | 55.68 |
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria and Sub-Saharan Africa. The majority of its revenue is derived from Nigeria.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.